Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.50 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553009 | 0.81 | ST14 (0.54) | ST14ABATHRH3MAOBLOXL2 | |
| SCHEMBL14477632 | 0.80 | MEN1 (0.33) | — | |
| SCHEMBL819826 | 0.79 | LTA4H (0.50) | HRH3 | |
| Hydrochloric Acid SCHEMBL724006 | 0.79 | ST14 (0.52) | ST14ABATHRH3MAOBLOXL2 | |
| SCHEMBL16141145 | 0.77 | TRPA1 (0.39) | — | |
| SCHEMBL19342361 | 0.77 | CA2 (0.50) | HRH3 | |
| SCHEMBL18927002 | 0.77 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL14727608 | 0.77 | SLC6A4 (0.38) | — | |
| SCHEMBL19497906 | 0.74 | THRB (0.49) | — | |
| SCHEMBL14924826 | 0.74 | IDO1 (0.41) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114983940-A | Bioactive nano micelle and synthesis method thereof | 汉中职业技术学院 | 2022-09-02 | — | — | CN | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | ST14 4306/4885ABAT 234/4885HRH3 244/4885 |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | ST14 3700/4885ABAT 4659/4885HRH3 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.